Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC Toward a Cure: Chemotherapy Plus TKI in EGFR-Mutant NSCLC
Dr Mark Kris discusses neoadjuvant approaches for patients non-small cell lung cancer with oncogenic drivers for which there are effective targeted therapies.Medscape Oncology
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Hematology-Oncology Commentary Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Health | Hematology | Lung Cancer | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Non-Small Cell Lung Cancer